Preliminary experience with dosimetry, response and patient reported outcome after (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aimed to evaluate dosimetry, safety and efficacy of (177)Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Fifteen patients each received two...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Fendler, Wolfgang P., Reinhardt, Svenja, Ilhan, Harun, Delker, Andreas, Böning, Guido, Gildehaus, Franz J., Stief, Christian, Bartenstein, Peter, Gratzke, Christian, Lehner, Sebastian, Rominger, Axel
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356905/
https://ncbi.nlm.nih.gov/pubmed/27683041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12240
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares